Business
NurExone Issues Annual Shareholder Letter
Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE:...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Issues Annual Shareholder LetterCalgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (\"we\", \"our\", the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy (\"ExoTherapy\") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from NurExone CEO Dr. Lior Shaltiel.Dear Shareholders, We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing our underlying technology, the awareness of a greater picture has intensified. The same technologies and science that will serve NurExone may be of great use and interest to other pharmaceutical companies for different exosome-based indications. So, going forward, we have decided that, in parallel with our vision for drug development, we will also pursue licensing and commercialization applications for our unique exosome technology. Go-Public Listing on the TSX Venture ExchangeFirst and foremost, we completed our public listing in Canada on the TSX Venture Exchange (TSXV), a well-recognized junior stock exchange in North America and began trading under the ticker symbol \"NRX\" in June 2022. Although our Company was founded in Israel, we decided it was in the best interest of the Company to expand our presence and grow our investor base in North America. By being listed on the TSXV, we are looking to build a strong network of North American investors as well as strengthen our relationship with the U.S. and Canadian sell-side investment community.U.S. Food and Drug Administration (FDA) Regulatory TimelineAs we scale up our research and product development, we continue to pursue healthcare regulatory approval from the U.S. Food and Drug Administration (FDA), which we believe is the gold standard of the biopharmaceutical industry for drug approval and enables us to fully commercialize our drug platform in one of the biggest healthcare markets in the world. The U.S. spinal cord injury (SCI) treatment market alone was estimated to be worth US$717.6 Million in 2020.1As far as we know, there are currently no other biopharmaceutical companies that utilize exosomes to develop a treatment for spinal cord in...